Search results
Your search for FMC7 returned no results
Showing 451 to 489 of 489 results for face
Showing 451 to 489 of 489 results for face
Weight management: lifestyle services for overweight or obese children and young people (PH47)
This guideline covers lifestyle weight management services for children and young people aged under 18 who are overweight or obese. It advises how to deliver effective weight management programmes that support children and young people to change their lifestyle and manage their weight.
Evidence-based recommendations on translaryngeal tracheostomy (TLT). This involves passing a tube from inside the windpipe to outside the neck to aid breathing.
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS40Show all sections
Sections for QS40
- Quality statements
- Quality statement 1: Assessing disease severity
- Quality statement 2: Assessing impact of disease
- Quality statement 3: Referring to specialist services
- Quality statement 4: Assessing cardiovascular risk
- Quality statement 5: Assessing for psoriatic arthritis
- Quality statement 6: Monitoring systemic therapy
- Update information
Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.
Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. This involves inserting titanium implants to replace broken bones in the face as part of orofacial reconstruction.
View recommendations for IPG449Show all sections
Sections for IPG449
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
Good practice guidance – Integrated process statement (PMG12)
Good practice guidance – Integrated process statement
This quality standard covers the health and wellbeing of looked-after children and young people (from birth to 18 years) and care leavers (including young people planning to leave care or under leaving care provisions). It is for all settings and services that work with and care for looked-after children and young people, wherever they are living (for example, with family or friends, with foster families or in residential care). It describes high-quality care in priority areas for improvement.
View quality statements for QS31Show all sections
Sections for QS31
- Quality statements
- Quality statement 1: Warm, nurturing care
- Quality statement 2: Collaborative working between services and professionals
- Quality statement 3: Stability and quality of placements
- Quality statement 4: Support to explore and make sense of identity and relationships
- Quality statement 5: Support from specialist and dedicated services
- Quality statement 6: Continuity of services for placements outside the local authority or health boundary
- Quality statement 7: Support to fulfil potential
This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
Good practice guidance – Interim process statement
Evidence summaries: new medicines – Interim process statement (PMG1)
Evidence summaries: new medicines – Interim process statement
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.
This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.
This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.
This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.
Depression in adults with a chronic physical health problem: recognition and management (CG91)
This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (IPG310)
Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.
View recommendations for IPG310Show all sections
Sections for IPG310
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis (IPG273)
Evidence-based recommendations on balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. This involves gently inflating a small balloon, which is introduced through the nose via a flexible tube, to help keep the sinus passages open and unobstructed.
View recommendations for IPG273Show all sections
Sections for IPG273
Lumbar infusion test for the investigation of normal pressure hydrocephalus (IPG263)
Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.
View recommendations for IPG263Show all sections
Sections for IPG263
Interstitial photodynamic therapy for malignant parotid tumours (IPG259)
Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.
View recommendations for IPG259Show all sections
Sections for IPG259
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Evidence-based recommendations on therapeutic sialendoscopy. This involves using a flexible tube to enter the salivary gland, and visualise and remove the stone.
View recommendations for IPG218Show all sections
Sections for IPG218
Evidence-based recommendations on tonsillectomy using laser. This involves using a laser to cut and remove tonsils and seal the blood vessels.
View recommendations for IPG186Show all sections
Sections for IPG186
Improving outcomes for people with brain and other central nervous system tumours (CSG10)
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
In development [GID-TA10883] Expected publication date: 18 September 2024
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: TBC
In development [GID-HTE10019] Expected publication date: 25 April 2024